Aprea Therapeutics Stock Drops After FDA Clinical Hold On Another Blood Cancer Study
After instituting a partial clinical hold on Aprea Therapeutics Inc’s (NASDAQ:APRE) myeloid malignancies program, the FDA has placed a clinical hold on Aprea’s lymphoid…
RBC Capital Maintains Sector Perform on Aprea Therapeutics, Lowers Price Target to $6
RBC Capital analyst Gregory Renza maintains Aprea Therapeutics (NASDAQ:APRE) with a Sector Perform and lowers the price target from $7 to $6.
Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials
The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc’s (NASDAQ:APRE) clinical trials of eprenetapopt (APR-246) combined with azacitidine in…
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Aprea Therapeutics Reports Partial Clinical Hold On Myeloid Malignancy Programs
Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S.
Analyzing Aprea Therapeutics’s Unusual Options Activity
On Wednesday, shares of Aprea Therapeutics (NASDAQ:APRE) saw unusual options activity. After the option alert, the stock price moved up to $5.2.
Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant
Aprea Therapeutics Inc (NASDAQ: APRE)
Aprea Therapeutics Announces Results From Phase 2 Trial Of Eprenetapopt + Azacitidine For Post-Transplant Maintenance Therapy In TP53 Mutant MDS And AML; Results Showed 58% Relapse Free Survival And 79% Overall Survival 1 Year Post Transplant
58% relapse free survival at 1 year post-transplant
79% overall survival at 1 year post-transplant
BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical